Lab company Quest pays $13 million to settle Medicare fraud lawsuit

Quest Diagnostics paid $13M to settle a lawsuit alleging false Medicare/Medicaid claims. The U.S. Attorney's Office accused the company of offering exclusive Giants game perks to secure referrals. Quest denied wrongdoing but settled to resolve the matter. The settlement does not determine liability or rule out future probes.

Original reporting
Published Nov 9, 2026, 10:47 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 10:54 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Lab company Quest pays $13 million to settle Medicare fraud lawsuit — source image
Decision brief

The 30-second read

$DGXBearishLow
01

Why it matters

The settlement resolves the current lawsuit but does not preclude further regulatory action, keeping compliance risk on the table.

02

Market read

A new legal settlement for Quest Diagnostics introduces modest downside risk and underscores sector‑wide compliance concerns.

03

What to watch

Potential for future investigations beyond the settlement and the impact on relationships with provider networks.

Relevance 6/10Novelty 7/10Timing: post‑settlement announcement

Background

Quest Diagnostics faced allegations of violating the Anti‑Kickback Statute by providing entertainment to providers in exchange for referrals, leading to a $13 million settlement with the DOJ.

Company-level read

Ticker impact

$DGXBearishMedium confidence
Context

Quest Diagnostics settled a $13 million Medicare fraud lawsuit, a new legal enforcement action affecting the company.

Expected impact

likely modest downward pressure as investors price in settlement cost and regulatory risk

Evidence & confidence

Settlement amount is modest but signals compliance concerns; no immediate financial hit beyond the payout.

Market effects

Highlights ongoing regulatory scrutiny of lab‑testing firms and could prompt tighter compliance spending in the sector.

Limited to U.S. healthcare and diagnostics markets.

Minimal; primarily a U.S. company issue.

Counterpoint

The settlement amount is small relative to Quest's size; the market may overreact, presenting a buying opportunity if the stock dips.

Key entities

  • Quest Diagnostics

    U.S. lab‑testing company that settled the Medicare fraud lawsuit.

  • U.S. Department of Justice

    Prosecuted the alleged anti‑kickback scheme.

Related articles

$DGXLow

Quest Diagnostics Pays $13 Million to Settle Kickback Allegations Involving New York Giants Tickets

Quest Diagnostics will pay $13M to settle allegations of illegal kickbacks, including New York Giants tickets, to healthcare providers. The U.S. Attorney's Office claims the company violated the Anti-Kickback Statute from 2013 to 2022, offering perks in exchange for business referrals. Quest denies wrongdoing but agreed to a settlement and a 5-year compliance agreement.

$DGXLow

Quest Diagnostics pays more than $13M to settle alleged kickback scheme, federal prosecutors say

Quest Diagnostics agreed to pay $13M to settle allegations of a kickback scheme involving gifts to hospital executives, including New York Giants game tickets, according to federal prosecutors. The scheme allegedly lasted from 2013 to 2022, with Quest billing government-funded medical plans. The company will also face five years of auditing. Quest reported $11B in 2025 revenue, up 7%.

$DGXLow

Quest Diagnostics pays $13M to settle kickback allegations involving NY Giants tickets

Quest Diagnostics agreed to pay $13M to settle allegations of providing illegal kickbacks, including NY Giants tickets, to healthcare providers for referrals, according to the U.S. Attorney’s Office of New Jersey. The settlement resolves claims of violating the Anti-Kickback Statute and submitting false claims to Medicare and Medicaid. Quest denies wrongdoing but agreed to the settlement to resolve the matter.

$DGXLow

Quest Diagnostics pays more than $13 million to settle allegations of illegal kickbacks involving Giants tickets, VIP events

Quest Diagnostics Inc. paid $13,014,576 plus interest to settle federal allegations of illegal kickbacks involving free New York Giants tickets and VIP events to induce patient referrals. The company violated the Anti-Kickback Statute and submitted false claims to Medicare and Medicaid programs, according to the U.S. Attorney’s Office. Quest also entered a five-year Corporate Integrity Agreement with HHS-OIG. Whistleblowers will receive nearly $2.5 million.

$LHMed

Labcorp, Quest urge RESULTS Act passage as lab payment cuts loom

Labcorp and Quest Diagnostics warn of revenue impacts from upcoming Medicare and Medicaid reimbursement cuts starting in 2027. Labcorp expects a $125 million hit, while Quest estimates a 1% revenue reduction in 2026. Both companies advocate for the passage of the RESULTS Act to reform the payment rate-setting process, citing concerns over patient access and lab viability.